ArticleJournal of spine research and surgery2026
Emerging Biologics in Lumbar Disc Degeneration: PRP, Stem Cell Therapy, and Pharmacotherapy in Mobility Restoration and Rehabilitation.
Article in Journal of spine research and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stiff Person Syndrome: Bridging Neuroimmunology and Rehabilitation for Improved Patient Outcomes.Archives of internal medicine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lumbar disc degeneration is a leading contributor to chronic low back pain and functional limitation worldwide, driven by progressive extracellular matrix breakdown, disc dehydration, inflammation, and cellular senescence. Conventional treatments-including pharmacotherapy, physical rehabilitation, and surgery-primarily address symptoms rather than the underlying degenerative cascade and often fail to restore disc structure or long-term mobility. Emerging biologic therapies have gained attention for their potential to modify disease progression and promote regeneration. This narrative review examines current evidence surrounding platelet-rich plasma, mesenchymal stem cell therapies, peptide analogs, and evolving pharmacologic agents in the management of lumbar disc degeneration, with particular emphasis on mobility restoration and rehabilitation integration. platelet-rich plasma and mesenchymal stem cell-based interventions demonstrate moderate improvements in pain and functional outcomes with generally favorable safety profiles, though durable structural regeneration remains unproven. Peptide analogs and molecular agents show promising preclinical regenerative and anti-inflammatory effects but lack robust human data and regulatory approval. Pharmacologic strategies targeting inflammatory and catabolic pathways may complement biologic therapies but remain largely investigational. The integration of biologics with structured rehabilitation and progressive loading appears critical for optimizing functional recovery. Despite encouraging advances, significant limitations persist, including heterogeneous protocols, limited high-quality randomized trials, and insufficient long-term data. Future research should prioritize standardization, comparative effectiveness studies, and multimodal treatment models to clarify the role of biologic therapies in restoring mobility and function in lumbar disc degeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.